Abstract
Abstract The kynurenine pathway of tryptophan oxidative metabolism plays a major role in the nervous and immune systems and has been implicated in a range of disease states. Much of the interest in the pathway has been centred around the role of quinolinic acid as an agonist at glutamate receptors sensitive to N -methyl- d -aspartate (NMDA) and kynurenic acid which blocks all the ionotropic glutamate receptors. In addition, it is clear that the pathway is important in modulating the level of oxidative stress in tissues, partly via the activation of blockade of NMDA receptors, but also via the generation of redox active compounds such as 3-hydroxykynurenine and 3-hydroxyanthranilic acid. Pharmacological interference with this pathway therefore presents a route for reducing oxidative tissue damage at several different metabolic steps, providing a valuable potential therapeutic target for new drug development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
